A Study of LY3314814 in Participants With Liver Impairment

Withdrawn before enrolling · Phase 1

Conditions studied: Hepatic Impairment

In brief

The purpose of the study is to determine whether LY3314814 can be safely prescribed in participants with liver impairment without a dose adjustment. Participants will be on study for 11 days with follow-up about 7 days afterward.

Key facts

Study ID

NCT03499041

Run by

Eli Lilly and Company

People needed

0

Starts

2018-06-01

Expected to finish

2018-12-01

Last updated by the study team

2018-06-28

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Have a Body Mass Index (BMI) of 18 to 40 kilogram per meter square (kg/m²), inclusive, at the time of screening

You may not qualify if…

• Have a history of or current significant ophthalmic disease, particularly any eye problem involving the retina
• Have moderate or severe vitiligo or any other clinically significant disorder of skin or hair pigmentation
• Have acute unstable neuropsychiatric disease
• Have active or uncontrolled neurologic disease, or clinically significant head injury

Where it is running

• Orange County Research Center — Tustin, California, United States
• Clinical Pharmacology of Miami — Miami, Florida, United States
• Orlando Clinical Research Ctr — Orlando, Florida, United States
• New Orleans Cntr for Clin Res — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.